Rohto Pharmaceutical Co., Ltd. reported mixed financial results for the first half of the fiscal year ending September 30, 2024, with net sales increasing by 8.8% to 139,082 million yen. However, operating income fell by 15.1% to 17,791 million yen, and profit attributable to owners dropped by 22.1% to 12,921 million yen due to rising costs and research expenses. Despite these challenges, the company saw strong sales growth in the Americas and Asia, expanded its global presence with 43 new subsidiaries, and remains optimistic about its full-year forecast.
